Mapi - Pharma (Mapi - Pharma) EV-to-EBITDA : 0.00 (As of May. 30, 2024)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mapi - Pharma's enterprise value is $0.00 Mil. Mapi - Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2015 was $-6.14 Mil. Therefore, Mapi - Pharma's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for Mapi - Pharma's EV-to-EBITDA or its related term are showing as below:

MAPI's EV-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 14.545
* Ranked among companies with meaningful EV-to-EBITDA only.

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-30), Mapi - Pharma's stock price is $0.00. Mapi - Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2015 was $0.000. Therefore, Mapi - Pharma's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Mapi - Pharma EV-to-EBITDA Historical Data

The historical data trend for Mapi - Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma EV-to-EBITDA Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

EV-to-EBITDA

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
EV-to-EBITDA	-	-	-	-	-

Competitive Comparison of Mapi - Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's EV-to-EBITDA falls into.

Mapi - Pharma EV-to-EBITDA Calculation

Mapi - Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	0.000	/	-6.141
	=	0.00

Mapi - Pharma's current Enterprise Value is $0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mapi - Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2015 was $-6.14 Mil.

Mapi - Pharma (NAS:MAPI) EV-to-EBITDA Explanation

Mapi - Pharma's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.00	/	0.000
	=	N/A

Mapi - Pharma's share price for today is $0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mapi - Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2015 was $0.000.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Mapi - Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.